Stemline Therapeutics, Inc. announced expansion of its Board of Directors to include members with expertise in commercial, legal and finance. Stemline has appointed Darren Cline, Executive Vice President, Commercial at Seattle Genetics, to its Board. Mr. Cline is a veteran biopharmaceutical executive with over 25 years of commercial experience, including in the hematology and oncology, orphan and ultra-orphan arenas. He has an established track record of success in commercial leadership roles. The Company also broadened its legal and financial expertise with the addition of Messrs. Dan Hume and Mark Sard to its Board. Mr. Hume is currently a managing partner at Kirby McInerney, LLP, where his law practice focuses on securities law regulation, structured finance, antitrust, and civil litigation. Mr. Hume is member of the board of directors of TG Therapeutics and National Holdings Corporation. Mr. Sard has a thirty-plus year career in venture capital, private equity, and underwriting. Mr. Sard is a founder and principal at Frontier Equities VC.